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Abstract
Clinical methods of detecting diabetic peripheral neuropathy (DPN) are not objective and
reproducible. We therefore evaluated if SUDOSCAN, a new method developed to provide a
quick, non-invasive and quantitative assessment of sudomotor function can reliably screen
for DPN. 70 subjects (45 with type 1 diabetes and 25 healthy volunteers [HV]) underwent
detailed assessments including clinical, neurophysiological and 5 standard cardiovascular
reflex tests (CARTs). Using the American Academy of Neurology criteria subjects were
classified into DPN and No-DPN groups. Based on CARTs subjects were also divided into
CAN, subclinical-CAN and no-CAN. Sudomotor function was assessed with measurement
of hand and foot Electrochemical Skin Conductance (ESC) and calculation of the CAN risk
score. Foot ESC (μS) was significantly lower in subjects with DPN [n = 24; 53.5(25.1)] com-
pared to the No-DPN [77.0(7.9)] and HV [77.1(14.3)] groups (ANCOVA p<0.001). Sensitiv-
ity and specificity of foot ESC for classifying DPN were 87.5% and 76.2%, respectively. The
area under the ROC curve (AUC) was 0.85. Subjects with CAN had significantly lower foot
[55.0(28.2)] and hand [53.5(19.6)] ESC compared to No-CAN [foot ESC, 72.1(12.2); hand
ESC 64.9(14.4)] and HV groups (ANCOVA p<0.001 and 0.001, respectively). ROC analysis
of CAN risk score to correctly classify CAN revealed a sensitivity of 65.0% and specificity of
80.0%. AUC was 0.75. Both foot and hand ESC demonstrated strong correlation with indi-
vidual parameters and composite scores of nerve conduction and CAN. SUDOSCAN, a
non-invasive and quick test, could be used as an objective screening test for DPN in busy
diabetic clinics, insuring adherence to current recommendation of annual assessments for
all diabetic patients that remains unfulfilled.
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Introduction
The Toronto Consensus meeting defined Diabetic peripheral neuropathy (DPN) as a symmet-
rical and length-dependent sensorimotor polyneuropathy attributable to metabolic and micro-
vessel alterations as a result of chronic hyperglycemia exposure [1]. It is now well recognised
that DPN has major impact on quality of life, morbidity [2], mortality [3,4] and considerable
health care costs [5]. Unfortunately, current bedside assessments for neuropathy such as the 10
gram monofilament [6], the Ipswich Touch Test [7], Vibratip [8] etc. are primarily aimed at
screening for those at risk of foot ulceration and tend to diagnose DPN when it is well estab-
lished. Late diagnosis hampers the benefits of early identification, the focus on early, intensified
diabetes control, and the prevention of neuropathy-related sequelae [9]. A recent study has
also found that there is significant variation on how clinical assessments are performed in prac-
tice and that the diagnosis of DPN is not always reproducible even when performed by experts
[10]. Moreover, these clinical methods rely on the cognitive function of the subject and are not
objective. This highlights the urgent need for an objective, quantitative screening test for DPN
in clinical practice that overcomes the limitations of current methods.
Changes in peripheral autonomic nervous system function are an early manifestation of dis-
tal small fiber neuropathy [11]. Sudomotor dysfunction is one of the earliest detectable abnor-
malities in distal small fiber neuropathies [11]. Sweat glands are innervated by sudomotor,
postganglionic, thin, unmyelinated cholinergic sympathetic C-fibres and a number of skin
biopsy studies have shown a reduction in the epidermal C-nerve fibers in patients with diabetes
[12]. Distal loss of sweating detected by the thermoregulatory sweat test correlated with sub-
normal quantitative sudomotor axon reflex response, an indication of a distal axonal neuropa-
thy [13]. Therefore, assessment of sudomotor function may provide an attractive tool to
evaluate peripheral small fibre neuropathy in diabetes [14].
SUDOSCAN is a new device developed to provide a quick, non-invasive and reproducible,
quantitative assessment of sudomotor function [Fig 1; 14–17]. Measurement is based on an
electrochemical reaction between electrodes and chloride ions, after stimulation of sweat
glands by a low-voltage current (<4volts) [14–17]. A measurement of conductance for the
hands and feet, that are rich in sweat glands, is generated from the derivative current associated
with the applied voltage [14]. SUDOSCAN shows good reproducibility in various physiological
conditions. Furthermore, due to its focus on chloride concentrations it is less dependent on
sweat rates than current methods used for assessment of sweat function [14–15]. However,
none of the previous studies used gold standard electrophysiological assessment to define
DPN. Hence, the aim of this study performed in subjects with type 1 diabetes (T1DM) was to
evaluate if SUDOSCAN can reliably screen for DPN that was carefully characterized by using
nerve conduction studies according to American Academy of Neurology guidelines.
Materials and Methods
A total of 70 subjects (45 with T1DM and 25 healthy volunteers—HV) underwent detailed
assessments including clinical and neurophysiological assessments to detect the presence and
quantify the severity of DPN. DPN cases were defined according to established American
Academy of Neurology consensus criteria using nerve conduction studies and clinical exami-
nation [18]. Cases with DPN had at least one neuropathic symptom or sign and at least one
abnormal nerve conduction parameter in both sensory (sural) and motor (peroneal or tibial)
nerves. Neuropathic symptoms were documented by completion of the NTSS-6 questionnaire
which included numbness, burning, prickling paraesthesias, dysesthesias and allodynia [19].
Abnormal neurological signs included abnormal temperature, light touch, 10g monofilament
(performed according to previously published criteria [20]) and absent or reduced knee/ankle
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reflexes. Neurological examination was performed according to the structured, validated Neu-
ropathic Impairment Score of the Lower Limbs (NIS[LL]) questionnaire [21]. All subjects also
underwent quantitative sensory assessments using the Computer Assisted Sensory Evaluation
IV system (CASE IV, W.R. Electronics, Stillwater, MN). Vibration and cooling detection
thresholds were acquired from the dorsal aspect of the right foot by employing standard tech-
niques [22, 23]. Nerve conduction studies were performed at a stable skin temperature of 31°C
and a room temperature of 24°C using a Medelec electrophysiological system (Synergy Oxford
Instruments, Oxford, U.K.). The following nerve attributes were measured: a) sural sensory
nerve action potential and conduction velocities, b) common peroneal nerve compound mus-
cle action potential, conduction velocity and distal latency and c) tibial motor nerve distal
latency. An overall neuropathy composite score (NCS—with a higher score indicating a more
severe neuropathy) derived from transformed percentile points of abnormalities in sural nerve
amplitude, tibial motor nerve distal latency, and peroneal motor nerve amplitude, latency and
velocity, was calculated.
In addition all subjects also underwent 5 cardiovascular autonomic reflex tests (CART)
according to the O’Brien protocol [24, 25]. Resting supine heart-rate and heart-rate responses
to provocation tests (deep breathing, Valsalva and lying/standing), in addition to lying-to-
standing blood pressure difference, were measured. Age adjusted normative data was used and
a diagnosis of CAN was made if at least one out of the five tests were abnormal. An overall
autonomic function test score (AFT score) was calculated based on age adjusted percentile
abnormalities of CARTs. The higher the score the more severe is the CAN.
Fig 1. SUDOSCAN.
doi:10.1371/journal.pone.0138224.g001
Screening for Diabetic Peripheral Neuropathy using SUDOSCAN
PLOSONE | DOI:10.1371/journal.pone.0138224 October 12, 2015 3 / 11
Finally, assessment of sudomotor function was performed using the SUDOSCAN test. This
new and quick method is based on an electrochemical reaction between sweat chloride and
stainless steel electrodes and has been validated in vitro and in previous clinical studies with
assessment of reproducibility [14–17]. Patients placed the palms of their hands and the soles of
their feet on stainless steel electrodes and an incremental low direct voltage (<4V) was applied
for about 2 minutes. Electrochemical skin conductance (ESC), a measure of sudomotor func-
tion, is obtained from the ratio between the current that is measured and voltage applied.
Quantitative results were expressed as ESC (microsiemens, μS) for the hands and feet, and a
CAN risk score (CAN-RS) derived from the ESC values and demographic data (BMI and age)
was calculated using an algorithm previously described [26]. Subjects with peripheral vascular
disease were not excluded from the study. All subjects gave written informed consent for par-
ticipating in this study which had prior ethics approval by the South Yorkshire and Humber
Regional Ethics Committee.
Statistics
Group demographic characteristics were compared using an analysis of variance (ANOVA).
Subjects with T1DM were divided into two DPN groups according to criteria defined above.
We used a univariate test (ANCOVA) to compare differences between groups (HV, No-DPN
and DPN) by calculating mean foot and hand ESC per group adjusted for age and weight as
fixed factors. A full factorial model was used with group difference as a contrast. T1DM sub-
jects were then divided into two CAN groups (No-CAN and CAN) according to criteria
defined above. A univariate test (ANCOVA) was used to compare differences between groups
(HV, No-CAN and CAN) by calculating mean foot and hand ESC per group adjusted for age
and weight as fixed factors. A full factorial model was used with group difference as a contrast.
The relation between mean foot and hand ESC and individual attributes of nerve function
NCS and CART (AFT score) was examined in more detail among subjects with diabetes using
Spearman’s Rank correlation coefficients. We also calculated the sensitivity, specificity and
area under the ROC curve to examine the performance of SUDOSCAN measures to correctly
identify subjects with DPN and CAN. Statistical analysis was done using statistical package
SPSS 20.0.
Results
Table 1 shows demographic and results of the neurophysiological and SUDOSCAN assess-
ments. Subjects with DPN [52.1(9.7) years] were significantly older than the No-DPN [40.6
(9.8), t-test p<0.001] and an older group of HV was recruited [48.1(16.4), ANOVA p = 0.01].
Subjects with diabetes [No-DPN 78.8(15.2) and DPN 83.3(14.4)] weighed more compared to
HV [73.3(13.6), ANOVA p = 0.06]. As differences were observed in age and weight, analysis
was adjusted based on these parameters.
Both foot and hand ESC demonstrated strong correlation with individual parameters and
composite scores of CAN and NCS scores (Table 2). 24 subjects had DPN. Foot ESC (μS) was
significantly lower in the neuropathy group [53.5(25.1)] compared to No-DPN [77.0(7.9)] and
HV [77.1(14.3), ANCOVA p<0.001, Fig 2a]. Similarly, hand ESC (μS) was also significantly
lower in subjects with DPN [49.2(20.4)] compared to No-DPN [66.4(11.5)] and HV [64.4
(14.3), ANCOVA p = 0.001, Fig 2b]. There was no significant difference in foot and hand ESC
between No-DPN and HV groups (p = 0.72 and p = 0.46 respectively). Fig 3a displays the prog-
nostic performance of SUDOSCAN ESC analyzed by Receiver Operating Curve (ROC) analysis
when choosing the American Neurological Association diagnostic criteria for DPN. When
choosing a foot ESC cut-off point of 77.0μS (optimal Youden index), sensitivity was 87.5%,
Screening for Diabetic Peripheral Neuropathy using SUDOSCAN
PLOSONE | DOI:10.1371/journal.pone.0138224 October 12, 2015 4 / 11
specificity was 76.2% and the Youden index was 0.64. The area under the ROC curve was 0.85.
The diagnostic performance of hand ESC was poorer in comparison to foot ESC (Table 3).
Next, we examined the differences in SUDOSCANmeasures between subjects categorized
according to CAN (n = 20) and No-CAN (n = 25, Table 1). Subjects with CAN had signifi-
cantly lower foot [55.0(28.2), Fig 2c] and hand [53.5(19.6), Fig 2d] ESC compared to No-CAN
[foot ESC, 72.1(12.2); hand ESC 64.9(14.4)] and HV groups (ANCOVA p<0.001 and 0.001
respectively). ROC analysis of CAN-RS to correctly classify T1DM subjects into CAN and No-
CAN is shown in Fig 3b. The sensitivity was 65.0%, specificity was 80.0% and the Youden
index was 0.45 with a CAN-RS cut-off point of 30.0% (optimal Youden index). The area
under the ROC curve was 0.75. The diagnostic performance of hand and foot ESC was weaker
in comparison (Table 3). DPN subjects [JND 20.0(4.1)] had higher vibration perception
Table 1. Demographics characteristics and SUDOSCAN outcomes of study subjects.
Healthy Volunteers No DPN DPN p value
N 25 21 24
Sex (Male, %) 14 (56.0%) 12 (57.1%) 16 (66.6%) 0.71
Age (years) 48.1 (16.4) 40.6 (9.8) 52.1 (9.7) 0.01
Height (m) 1.71 (8.3) 1.71 (8.8) 1.72 (8.7) 0.84
Weight (Kg) 73.3 (13.6) 78.8 (15.2) 83.3 (14.4) 0.06
Systolic BP (mmHg) 137.3 (16.1) 130.8 (14.9) 134.2 (15.8) 0.38
HbA1c (mmol/mol) 73.3 (9.0) 77.8 (21.7) 0.38
Duration of Diabetes (years) 17.2 (9.9) 29.7 (13.4) 0.02
Vibration JND 15.7 (3.3) 20.0 (4.1) 0.001
Sural Amplitude (mV) 9.10 (3.1–27.5) 0.0 (0.0–7.0) <0.001
Peroneal Velocity (m/s) 42.5 (36–52) 32.0 (0.0–44.2) <0.001
Peroneal Amplitude (mV) 1.8 (0.20–6.2) 0.30 (0.0–4.0) <0.001
Peroneal Distal Latency (mS) 4.80 (3.5–6.1) 4.75 (0.0–7.7) 0.41
Tibial Distal Latency (mS) 4.92 (3.4–6.4) 5.85 (0.0–8.1) 0.41
NCS score 1.00 (0.0–4.0) 10.5 (5.0–15.0) <0.001
FESC (μS) 77.1 (14.3) 77.0 (7.9) 53.5 (25.1) <0.001
HESC (μS) 64.4 (14.3) 66.4 (11.5) 49.2 (20.4) 0.001
CAN-RS (%) 21.1 (16.1) 17.6 (11.4) 32.1 (8.8) 0.001
Healthy Volunteers No-CAN CAN p value
n 25 25 20
Sex (Male, %) 14 (56.0%) 13 (52.0%) 13 (65.0%) 0.26
Age (years) 48.1 (16.4) 43.6 (10.9) 50.6 (10.7) 0.20
Height (m) 1.71 (8.3) 1.71 (9.8) 1.71 (7.5) 0.98
Weight (Kg) 73.3 (13.6) 79.0 (15.5) 84.0 (13.8) 0.05
Systolic BP (mmHg) 137.3 (16.1) 132.0 (14.1) 133.4 (16.9) 0.47
HbA1c (mmol/mol) 73.8 (9.6) 78.1 (23.3) 0.41
Duration of Diabetes (years) 19.4 (11.6) 28.9 (13.7) 0.02
R-R Deep Breathing 1.29 (0.1) 1.32 (0.2) 1.14 (0.1) <0.001
AFT Score 0.0 0.0 4.0 (1.0–12.0) <0.001
FESC 77.1 (8.6) 72.1 (12.2) 55.0 (28.2) <0.001
HESC 64.4 (14.3) 64.9 (14.4) 53.5 (19.6) 0.001
CAN-RS 21.1 (16.1) 20.8 (11.5) 31.0 (11.2) 0.02
JND, Just Noticeable Difference; NCS, Nerve Conduction Study; AFT, Autonomic Function Tests; FESC, Foot Electrochemical Skin Conductance; HESC,
Hand Electrochemical Skin Conductance; CAN, Cardiac Autonomic Neuropathy, CAN-RS, Cardiac Autonomic Neuropathy Risk Score.
doi:10.1371/journal.pone.0138224.t001
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threshold compared to No-DPN [JND 15.7(3.3); p = 0.001]. We found a significant negative
correlation between vibration JND with both FESC (ρ = -0.46, p = 0.002) and HESC (ρ = -0.40,
p = 0.007). No adverse events or discomfort during and after measurement were reported.
Conclusions
Currently, in our busy diabetic clinics we do not have a quantitative early marker of DPN. The
measures we routinely use such as the 10g monofilament testing or peripheral neurological
examination using other bedside instruments are crude, and detect the disease very late in its
natural history. The situation is different for the early and accurate detection of retinopathy
using the fundus camera as well as nephropathy by measuring microalbuminuria and eGFR.
This has recently resulted in retinopathy no longer being the commenest casue of working age
blindness in the UK. Unfortunately, by the time neuropathy is detected it is often very well
established and consequently impossible to reverse and very difficult to halt the inexorable neu-
ropathic process. Many of these patients end up in the foot clinic and have a very poor outcome
with 5-year mortality close to 50% [27]. Early identifications of subjects with DPN using novel
non-invasive methods will allow intensified treatment for blood glucose and cardiovascular
risk factors in order to prevent or halt the progression of DPN. This is critically important as
neuropathy is associated with much patient morbidity (foot ulceration, amputations, disabling
pain etc.) and also mortality [2–4, 28]. Clearly, therefore the development of non-invasive,
quick and sensitive measures of neuropathy has a most sound rationale.
In this study, that involved careful characterization of DPN using Gold-standard methodol-
ogy according to recommendation of the American Academy of Neurology [18] unlike previ-
ous studies, we have demonstrated that SUDOSCAN has an excellent sensitivity (87.5%) and
good specificity (76.2%) in detecting DPN. As expected foot ECS results detect neuropathy
more sensitively than hand. Furthermore, foot and hand ESC demonstrated strong correlation
with individual parameters and composite scores of nerve conduction. This demonstrates a
close association between severity of SUDOSCANmeasures with assessments of neuropathy
severity. The area under the ROC curve showed a significant result for foot ECS (0.85,
p<0.001). Our study has also showed that SUDOSCAN has a moderate sensitivity of 65.0%
and specificity of 80.0% to correctly diagnose CAN. The area under the ROC curve was 0.75.
These results are in accordance with study by Yajnik et al. [26] who used two abnormal Ewing
tests as a reference for CAN, and found an area under the ROC curve for SUDOSCAN of 0.74,
Table 2. Correlation of SUDOSCANMeasures with Vibration Detection Threshold, Nerve Conduction Studies and Cardiac Autonomic Function
Tests.
FESC p HESC p CAN-RS p
Vibration JND -0.49 0.001 -0.36 0.01
Sural Amplitude (mV) 0.51 <0.001 0.43 0.003
Peroneal Velocity (m/s) 0.75 <0.001 0.70 <0.001
Peroneal Amplitude (mV) 0.55 <0.001 0.20 0.20
Peroneal Distal Latency (mS) 0.32 0.03 0.01 0.92
Tibial Distal Latency (mS) -0.14 0.36 -0.14 0.35
NCS Z-score -0.62 <0.001 -0.52 <0.001
R-R Deep Breathing 0.37 0.005 0.35 0.008 0.41 0.001
AFT Score -0.41 0.001 -0.47 <0.001 -0.37 0.003
JND, Just Noticeable Difference; NCS, Nerve Conduction Studies; AFT, Autonomic Function Tests; FESC, Foot Electrochemical Skin Conductance;
HESC, Hand Electrochemical Skin Conductance; CAN-RS, Cardiac Autonomic Neuropathy Risk Score.
doi:10.1371/journal.pone.0138224.t002
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with a sensitivity of 92% and specificity of 49% [26]. Lower performance of CAN-RS in our
study may be explained by the fact that this risk score was defined on previous studies per-
formed in patients with T2DM [26].
A number of recent studies have looked at the potential utility of SUDOSCAN as a point-
of-care device for detecting DPN. However, unlike the present study none of them used nerve
conduction studies to characterize DPN. In a study involving 83 patients with both T1 and
T2DM by Casellini et al. Sudoscan was found to have a similar sensitivity (78%) and specificity
(92%) to our study in detecting neuropathy diagnosed by clinical exam (Neuropathy
Impairment Score of the Lower Limbs—NIS-LL) with area under the curve in their ROC
exactly the same as in our study at 0.85 [14]. Yajnik et al. [29] studied 265 diabetic patients and
Fig 2. Box and whisker plots of SUDOSCAN outcomes of each study group. A, Foot Electrochemical Skin Conductance (FESC, μS) in healthy
volunteers and subjects with type 1 diabetes divided into subjects with no diabetic peripheral neuropathy (No DPN) and DPN; B, Hand
Electrochemical Skin Conductance (HESC, μS) in HV, No DPN and DPN groups; C, FESC in HV and subjects with type 1 diabetes divided into
subjects with no Cardiac Autonomic Neuropathy (No CAN) and CAN; D, HESC in HV, No CAN and CAN groups.
doi:10.1371/journal.pone.0138224.g002
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found that lower foot ESC was significantly associated both with increasing symptoms (MNSI
A) and increasing score on physical abnormalities (MNSI B). Lower foot ESC was also signifi-
cantly associated with increasing VPT (P< 0.01), and with a higher number of abnormal CAN
results (P< 0.05). They concluded that sudomotor dysfunction testing may be a simple test to
alert physicians to peripheral nerve and cardiac sympathetic dysfunction, highlighting that the
ease of performance could make SUDOSCAN useful in the busy diabetic clinic [29]. Mayaudon
et al. [15] measured sensitivity, specificity, and reproducibility of SUDOSCAN among 133
Fig 3. Graphic presentation of the diagnostic performance of (A) Foot Electrochemical Skin Conductance (FESC, μS) and (B) Cardiac Autonomic
Neuropathy Risk Score (CAN-RS) by Receiver Operating Curve (ROC) analysis for diabetic peripheral neuropathy (A) and cardiac autonomic
neuropathy (B, CAN).
doi:10.1371/journal.pone.0138224.g003
Table 3. Receiver Operating Curve (ROC) analysis of classification of diabetic peripheral neuropathy
(DPN) and cardiac autonomic neuropathy (CAN).
FESC HESC CAN-RS
DPN Classiﬁcation
Sensitivity (%) 87.5 41.7
Speciﬁcity (%) 76.2 100.0
Youden Index 0.64 0.42
Area Under ROC 0.85 0.74
Cut-off point (μS) 77.0 42.0
CAN Classiﬁcation
Sensitivity (%) 60.0 45.0 65.0
Speciﬁcity (%) 76.0 96.0 80.0
Youden Index 0.36 0.41 0.45
Area Under ROC 0.66 0.74 0.75
Cut-off point (μS for ESC, % for CAN-RS) 69.0 42.0 30.0
FESC, Foot Electrochemical Skin Conductance; HESC, Hand Electrochemical Skin Conductance;
CAN-RS, Cardiac Autonomic Neuropathy Risk Score.
doi:10.1371/journal.pone.0138224.t003
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T2DM patients compared with 41 HVs. ESC showed a sensitivity of 75% and a specificity of
100%, with an area under the ROC curve of 0.88, similar to our present study. Another study
involving 142 diabetes patients showed that reduction in foot ESC measurements correlated
with an increasing VPT [16]. Bland–Altman plots indicated good reproducibility between two
measurements [16]. Thus, our findings are in keeping with other recent studies. Even though
the number of patients included in our study was small, unlike previous studies, all underwent
careful characterization for peripheral neuropathy using Gold standard AAN criteria [18]. Fur-
thermore, unlike previous studies we recruited T1DM subjects only to avoid a potential con-
found due to type of diabetes [30].
Currently, there are a number of validated methods of assessing sudomotor function [11].
However, none are suitable for use in the busy diabetic clinic due to the requirements of very
specialized equipment, complicated patient preparation, highly trained technicians for test per-
formance and/or interpretation, and prolonged testing time [14]. The potential use of SUDOS-
CAN appears to address all these disadvantages, as it is completely non invasive, can be
performed in less than 5 minutes, doesn’t require any patient preparation or cooperation, and
specialist training of the assessor is not necessary. The fact that it provides a ready objective
and quantitative measure of DPN is particularly appealing, as this will allow the assessment of
disease progression. In an international collaborative study we have recently shown that cur-
rent clinical methods of detecting peripheral neuropathy are not reliable with significant vari-
ability even when performed by experts [10]. The use of such as quick, simple and objective
measure of small-fibre neuropathy as screening measure in the busy diabetic clinic is therefore
appealing. There are now a number of point of care devices that have been assessed for diagno-
sis and screening of DPN [31–35]. The concurrent validity results reported here for SUDOS-
CAN are comparable to these devices. The major limitation of many of these devices is the low
specificity for detecting DPN. This suggests that although they may perform poorly on their
own, in combination their performance may improve sufficiently to justify screening for DPN.
Further studies will be required to assess this formally.
In conclusion, the results of our study suggest that peripheral sudomotor function; evalu-
ated using SUDOSCAN is a reliable, objective and quantitative way which may be included as
a screening tool for DPN. Prospective studies are required to investigate if abnormal SUDOS-
CAN results are predictive of the development of established DPN and hard outcomes such as
foot ulceration.
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